Search Results - "LOKHORST, Henk"

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma by Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W.C.J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A.Kate

“…Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent…”
Get full text

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond by van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.

“…Summary CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on…”
Get full text

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization by Drent, Esther, Themeli, Maria, Poels, Renée, de Jong-Korlaar, Regina, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C.M., Zweegman, Sonja, van de Donk, Niels W.C.J., Groen, Richard W.J., Lokhorst, Henk M., Mutis, Tuna

“…Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed surface antigens on tumor cells. The low expression of…”
Get full text

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma by Nijhof, Inger S., Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E., Syed, Khaja, Groen, Richard W.J., van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C., Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C., Mutis, Tuna, Lokhorst, Henk M., Sasser, A.Kate, van de Donk, Niels W.C.J.

“…The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single agent activity in heavily pretreated relapsed and refractory multiple…”
Get full text

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design by Drent, Esther, Poels, Renée, Mulders, Manon J, van de Donk, Niels W C J, Themeli, Maria, Lokhorst, Henk M, Mutis, Tuna

“…Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic…”
Get full text

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma by van de Donk, Niels W.C.J., Moreau, Philippe, Plesner, Torben, Palumbo, Antonio, Gay, Francesca, Laubach, Jacob P., Malavasi, Fabio, Avet-Loiseau, Hervé, Mateos, Maria-Victoria, Sonneveld, Pieter, Lokhorst, Henk M., Richardson, Paul G.

“…Immunotherapeutic strategies are emerging as promising therapeutic approaches in multiple myeloma (MM), with several monoclonal antibodies in advanced stages…”
Get full text

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells by Drent, Esther, Poels, Renée, Ruiter, Ruud, van de Donk, Niels W C J, Zweegman, Sonja, Yuan, Huipin, de Bruijn, Joost, Sadelain, Michel, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna, Themeli, Maria

“…Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR) requires specific attention to restrict possible detrimental…”
Get full text

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group by Palumbo, Antonio, Avet-Loiseau, Hervé, Oliva, Stefania, Lokhorst, Henk M, Goldschmidt, Hartmut, Rosinol, Laura, Richardson, Paul, Caltagirone, Simona, Lahuerta, Juan José, Facon, Thierry, Bringhen, Sara, Gay, Francesca, Attal, Michel, Passera, Roberto, Spencer, Andrew, Offidani, Massimo, Kumar, Shaji, Musto, Pellegrino, Lonial, Sagar, Petrucci, Maria T, Orlowski, Robert Z, Zamagni, Elena, Morgan, Gareth, Dimopoulos, Meletios A, Durie, Brian G M, Anderson, Kenneth C, Sonneveld, Pieter, San Miguel, Jésus, Cavo, Michele, Rajkumar, S Vincent, Moreau, Philippe

“…The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the…”
Get full text

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update by Nijhof, Inger S., van de Donk, Niels W. C. J., Zweegman, Sonja, Lokhorst, Henk M.

“…Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be…”
Get full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial by SONNEVELD, Pieter, SCHMIDT-WOLF, Ingo G. H, WEISEL, Katja C, WITTEBOL, Shulamiet, BOS, Gerard M. J, STEVENS-KROEF, Marian, SCHEID, Christof, PFREUNDSCHUH, Michael, HOSE, Dirk, JAUCH, Anna, DER VELDE, Helgi Van, RAYMAKERS, Reinier, DER HOLT, Bronno Van, SCHAAFSMA, Martijn R, KERSTEN, Marie-Jose, MARWIJK-KOOY, Marinus Van, DUEHRSEN, Ulrich, LINDEMANN, Walter, WIJERMANS, Pierre W, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut M, EL JARARI, Laila, BERTSCH, Uta, SALWENDER, Hans, ZWEEGMAN, Sonja, VELLENGA, Edo, BROYL, Annemiek, BLAU, Igor W

“…We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). In all, 827 eligible patients…”
Get full text

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials by SONNEVELD, Pieter, GOLDSCHMIDT, Hartmut, DESAI, Avinash, CAKANA, Andrew, LIU, Kevin, VAN DE VELDE, Helgi, ESSELTINE, Dixie-Lee, MOREAU, Philippe, ROSIÑOL, Laura, BLADE, Joan, JOSE LAHUERTA, Juan, CAVO, Michele, TACCHETTI, Paola, ZAMAGNI, Elena, ATTAL, Michel, LOKHORST, Henk M

“…To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

“…The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled…”
Get full text

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors by de Weers, Michel, Tai, Yu-Tzu, van der Veer, Michael S, Bakker, Joost M, Vink, Tom, Jacobs, Daniëlle C H, Oomen, Lukas A, Peipp, Matthias, Valerius, Thomas, Slootstra, Jerry W, Mutis, Tuna, Bleeker, Wim K, Anderson, Kenneth C, Lokhorst, Henk M, van de Winkel, Jan G J, Parren, Paul W H I

“…CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for…”
Get full text

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib by Nijhof, Inger S, Groen, Richard W J, Noort, Willy A, van Kessel, Berris, de Jong-Korlaar, Regina, Bakker, Joost, van Bueren, Jeroen J L, Parren, Paul W H I, Lokhorst, Henk M, van de Donk, Niels W C J, Martens, Anton C M, Mutis, Tuna

“…Novel therapeutic agents have significantly improved the survival of patients with multiple myeloma. Nonetheless, the prognosis of patients with multiple…”
Get full text

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma by Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A. Kate, Guckert, Mary E., de Boer, Carla, Khokhar, Nushmia Z., Yeh, Howard, Clemens, Pamela L., Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

“…Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study…”
Get full text

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma by Drent, Esther, Groen, Richard W J, Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna

“…Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression…”
Get full text

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment by Clemens, Pamela L., Yan, Xiaoyu, Lokhorst, Henk M., Lonial, Sagar, Losic, Nedjad, Khan, Imran, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Zhou, Honghui, Puchalski, Thomas, Xu, Xu Steven

“…Daratumumab is a CD38 monoclonal antibody recently approved for the treatment of multiple myeloma (MM). We report daratumumab pharmacokinetic data from GEN501,…”
Get full text

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab by Krejcik, Jakub, Frerichs, Kris A, Nijhof, Inger S, van Kessel, Berris, van Velzen, Jeroen F, Bloem, Andries C, Broekmans, Marloes E C, Zweegman, Sonja, van Meerloo, Johan, Musters, René J P, Poddighe, Pino J, Groen, Richard W J, Chiu, Christopher, Plesner, Torben, Lokhorst, Henk M, Sasser, A Kate, Mutis, Tuna, van de Donk, Niels W C J

“…Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical…”
Get full text

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action by Adams, Homer C., Stevenaert, Frederik, Krejcik, Jakub, Van der Borght, Koen, Smets, Tina, Bald, Jaime, Abraham, Yann, Ceulemans, Hugo, Chiu, Christopher, Vanhoof, Greet, Usmani, Saad Z., Plesner, Torben, Lonial, Sagar, Nijhof, Inger, Lokhorst, Henk M., Mutis, Tuna, Donk, Niels W.C.J., Sasser, Amy Kate, Casneuf, Tineke

“…Daratumumab is a CD38‐targeted human monoclonal antibody with direct anti‐myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory…”
Get full text